A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

NCT06745323 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

252

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer (SCLC)

Interventions

DRUG: Tarlatamab

Sponsor

Amgen